Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1995 1
1996 1
2000 2
2002 2
2004 3
2005 4
2006 5
2007 4
2008 7
2009 11
2010 26
2011 16
2012 24
2013 24
2014 13
2015 16
2016 13
2017 8
2018 7
2019 13
2020 14
2021 16
2022 16
2023 8
2024 9
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

231 results

Results by year

Filters applied: . Clear all
Page 1
Causal or casual?
Egberts TC. Egberts TC. Pharmacoepidemiol Drug Saf. 2005 Jun;14(6):365-6. doi: 10.1002/pds.1094. Pharmacoepidemiol Drug Saf. 2005. PMID: 15924331 No abstract available.
Association of busulfan exposure and outcomes after HCT for patients with an inborn error of immunity.
Bognàr T, Garcia-Rosa M, Lalmohamed A, Güngör T, Hauri-Hohl M, Prockop S, Oram L, Pai SY, Brooks J, Savic RM, Dvorak CC, Long-Boyle JR, Krajinovic M, Bittencourt H, Teyssier AC, Théorêt Y, Martinez C, Egberts TCG, Morales E, Slatter M, Cuvelier GDE, Chiesa R, Wynn RF, Coussons M, Cicalese MP, Ansari M, Long SE, Ebens CL, Lust H, Chaudhury S, Nath CE, Shaw PJ, Keogh SJ, van der Stoep MYEC, Bredius R, Lindemans CA, Boelens JJ, Bartelink IH. Bognàr T, et al. Among authors: egberts tcg. Blood Adv. 2024 Oct 8;8(19):5137-5145. doi: 10.1182/bloodadvances.2024013275. Blood Adv. 2024. PMID: 39074263 Free PMC article.
Traceability of biologicals: present challenges in pharmacovigilance.
Vermeer NS, Spierings I, Mantel-Teeuwisse AK, Straus SM, Giezen TJ, Leufkens HG, Egberts TC, De Bruin ML. Vermeer NS, et al. Among authors: egberts tc. Expert Opin Drug Saf. 2015 Jan;14(1):63-72. doi: 10.1517/14740338.2015.972362. Epub 2014 Nov 5. Expert Opin Drug Saf. 2015. PMID: 25369769 Review.
Paediatric Drug Development and Formulation Design-a European Perspective.
Van Riet-Nales DA, Kozarewicz P, Aylward B, de Vries R, Egberts TC, Rademaker CM, Schobben AF. Van Riet-Nales DA, et al. Among authors: egberts tc. AAPS PharmSciTech. 2017 Feb;18(2):241-249. doi: 10.1208/s12249-016-0558-3. Epub 2016 Jun 7. AAPS PharmSciTech. 2017. PMID: 27270905 Review.
Switching TNFα inhibitors: Patterns and determinants.
Meijboom RW, Gardarsdottir H, Becker ML, de Groot MCH, Movig KLL, Kuijvenhoven J, Egberts TCG, Leufkens HGM, Giezen TJ. Meijboom RW, et al. Among authors: egberts tcg. Pharmacol Res Perspect. 2021 Aug;9(4):e00843. doi: 10.1002/prp2.843. Pharmacol Res Perspect. 2021. PMID: 34302442 Free PMC article.
Drug-related problems in hospitalised patients.
van den Bemt PM, Egberts TC, de Jong-van den Berg LT, Brouwers JR. van den Bemt PM, et al. Among authors: egberts tc. Drug Saf. 2000 Apr;22(4):321-33. doi: 10.2165/00002018-200022040-00005. Drug Saf. 2000. PMID: 10789826 Review.
The association between skeletal muscle measures and chemotherapy-induced toxicity in non-small cell lung cancer patients.
de Jong C, Chargi N, Herder GJM, van Haarlem SWA, van der Meer F, van Lindert ASR, Ten Heuvel A, Brouwer J, de Jong PA, Devriese LA, Huitema ADR, Egberts TCG, de Bree R, Deneer VHM. de Jong C, et al. Among authors: egberts tcg. J Cachexia Sarcopenia Muscle. 2022 Jun;13(3):1554-1564. doi: 10.1002/jcsm.12967. Epub 2022 Mar 18. J Cachexia Sarcopenia Muscle. 2022. PMID: 35301821 Free PMC article.
231 results